Figure 8.
Captopril and losartan do not change soluble Aβ42 levels in flies expressing Aβ42 using a gmr or elav driver. A, Western blottings using samples from gmr-GAL4-UAS-GFP>UAS-C99V717I and gmr-GAL4-UAS-GFP>UAS-Aβ42 heads with or without drug treatments are shown as labeled. Each condition was tested with three biological replicates (N = 3). Kruskal–Wallis ANOVA analysis showed that both captopril and losartan had no significant effects on the levels of soluble Aβ42 in both gmr>C99V717I and gmr>Aβ42 flies at 7 d (p = 0.6286 and p = 0.2964, respectively). B, Levels of Aβ42 in elav-GAL4>UAS-Aβ42 heads at 28 d after eclosion were measured using human Aβ42 ELISA. The two-tailed unpaired t test showed that captopril had no significant effect on Aβ42 levels when compared with no drug condition (p = 0.31). A similar result was observed in elav-GAL4>UAS-Aβ42 flies treated with losartan (p = 0.5182). Each condition was tested with three technical replicates and two biological replicates in total (N = 2, n = 3). Data are shown as mean ± SEM; n.s., not significant.